



For more information contact:
Mattson Communications, Inc.
Kathy Mattson
312-988-9352
kathy@mattsonpr.com

TransMolecular, Inc.
Alyssa Vanderpool
617-995-3050 ext. 302
vanderpool@transmolecular.com

TransMolecular Appoints Jonathan B. Lloyd Jones As Vice President of Finance

Cambridge, Mass. – April 4, 2006 – TransMolecular, Inc., a biotechnology company focused on cancer drug development, today announced the appointment of Jonathan B. Lloyd Jones to the position of Vice President of Finance. He joins TransMolecular with more than 20 years of financial management and accounting experience. Mr. Lloyd Jones will be responsible for the company's financial and controllership functions, information technology and operations management.

“Jonathan brings significant operations experience in finance, valuation and market analysis, as well as direct expertise in managing the financial operations of a global biotechnology company,” said E. Michael Egan, President and CEO of TransMolecular. “We are excited to have Jonathan join our team to enhance our financial management capabilities.”

Mr. Lloyd Jones joins TransMolecular from Genzyme Corporation, one of the world's leading biotech companies, where he was Senior Director of Corporate Development. His experience at Genzyme includes negotiating multi-million dollar strategic acquisitions and in-licensing opportunities. Mr. Lloyd Jones was also recognized as a leader in due diligence management and valuation analysis.

- more -

Prior to Genzyme, Mr. Lloyd Jones was Manager of Operations and Finance at the Nassau, Bahamas based Royal Bank of Scotland Limited, a registered Private Bank and Trust Company within The Royal Bank of Scotland Group. In this position, he developed and implemented a restructuring plan that resulted in a 35 percent reduction in operating expenses and was responsible for all financial, management and regulatory reporting, back office and information technology operations.

Prior to this position, Mr. Lloyd Jones was a senior auditor for member firms of Ernst & Young and Deloitte Touche Tohmatsu. He is a Chartered Accountant and holds a MBA with a dual major in strategic management and finance from The Wharton School at the University of Pennsylvania and a B.S. in business studies from The University of Bradford in England.

"I look forward to working with Michael and his team to take TransMolecular to the next level," said Mr. Lloyd Jones. "We share a commitment to innovative research in support of patients suffering from cancer. I am confident that together we will deliver highly effective treatments built on a solid and sustainable business foundation."

About TransMolecular, Inc.

TransMolecular, Inc. is a privately held, venture capital backed biotechnology company committed to discovering, developing and commercializing novel and proprietary products to diagnose and treat cancer diseases having inadequate pharmaceutical alternatives. Research on TransMolecular's product pipeline based on a small peptide derived from scorpion venom that is expected to be useful in treating a wide variety of cancers is ongoing. More information can be found at www.transmolecular.com.

####